Connect with us

News

NIH Grant terminations disproportionately impact minority scientists, research finds

Published

on

Women, BIPOC and LGBTQ+ scientists were hit hardest by NIH grant terminations, a survey of nearly 1,000 US researchers has found.

The study surveyed 941 investigators whose National Institutes of Health grants were terminated in 2025, and suggests the policy changes may deepen existing disparities in the US biomedical research workforce.

Between January and May 2025, the National Institutes of Health terminated more than 2,000 research grants after shifting agency priorities.

Many of the affected grants focused on health disparities, including research related to BIPOC communities and sexual and gender minorities. I

n addition, about 600 grants were cancelled through institution-wide actions aimed at addressing alleged campus antisemitism.

The research, conducted by the University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science, found that researchers from marginalised groups were both overrepresented among those whose grants were cancelled and more likely to have their work specifically targeted for termination.

Rebecca Fielding-Miller is associate professor at the UC San Diego Herbert Wertheim School of Public Health and Human Longevity Science and senior author of the study.

She said: “These grant terminations didn’t just disrupt specific research projects, they also disrupted the careers of many scientists who study the health of marginalised communities.

“When funding for these topics disappears, the researchers with the deepest expertise in them are often the ones most directly affected.”

The National Institutes of Health is the world’s largest public funder of biomedical research, investing roughly US$47bn annually.

Because of the scale of this investment, US research priorities help shape the direction of health science innovations globally.

To understand who was most affected, the team surveyed investigators whose terminated grants were documented in the Grant Witness database.

Of 1,918 investigators invited to participate, 941 completed the survey.

In order to categorise terminations by justification, investigators were asked to select from eight possible reasons for the termination.

For example, participants were considered to have received an equity-related termination if they indicated their grant was terminated due to “amorphous equity objectives”, and a gender-related termination if they indicated their grant was terminated due to “gender identity”.

The analysis found that nearly half, 48.6 per cent, of investigators whose grants were terminated for equity-related reasons identified as BIPOC.

Among grants terminated for gender-related reasons, 60 per cent of investigators identified as sexual or gender minorities, including 16.5 per cent who were transgender or nonbinary.

Disparities extended beyond simple representation. Among investigators whose grants were terminated, BIPOC women and transgender or nonbinary researchers had nearly three times higher odds of receiving an equity-related termination than White men.

Sexual and gender minority investigators were more than 11 times more likely to receive a gender-related termination than heterosexual, cisgender researchers.

The study also found that 20.5 per cent of investigators affected by institution-wide terminations tied to alleged antisemitism identified as Jewish, raising questions about the effectiveness of those actions as a mechanism to protect Jewish researchers.

The findings build on earlier research showing that disparities already exist in the biomedical funding system.

Previous studies have found that scientists from underrepresented backgrounds are more likely to study health disparities or community-based topics that historically receive less funding.

“When funding disruptions disproportionately affect researchers who focus on health disparities, the consequences go far beyond individual careers,” Fielding-Miller said.

“They also shape which scientific questions get asked, and whose health ultimately receives attention.”

The authors warn that the effects could persist for years.

Because research careers and funding success tend to build cumulatively over time, losing even a single grant can derail projects, disrupt community partnerships and limit future funding opportunities, particularly for early-career investigators.

Looking ahead, the researchers say restoring and sustaining funding for equity-related health research will be critical to maintaining a diverse scientific workforce and ensuring that biomedical research reflects the needs of all communities.

“If we want a scientific enterprise that serves everyone,” Fielding-Miller said.

“We have to ensure that scientists studying the health of marginalised communities are able to continue their work.”

News

Menstrual health innovation shortlist revealed

Published

on

We are thrilled to announce the shortlist for the Menstrual Health Innovation Award at the third annual FemTech World Awards.

This award, sponsored by Premom exists to celebrate the trailblazers redefining what menstrual health means in the modern world.

It recognises breakthrough products, services, and initiatives that are pushing boundaries in technology, product design, education, accessibility, and destigmatisation.

Premom’s innovative ovulation prediction app combines a digital ovulation test reader, intelligent fertility charting, and customised cycle insights to simplify the path to motherhood.

Sister company easy@Home was the first brand in the USA to offer personalised testing solutions and devices, and has become the largest volume seller of ovulation tests in the country.

Premom’s sponsorship of this award reflects a shared commitment to empowering women with better tools, better knowledge and better outcomes across every stage of their reproductive health journey.

This year’s shortlist is a testament to the remarkable breadth of innovation happening across the femtech landscape, from wearable bioelectronics to mission-driven apps reaching underserved communities across the globe.

Congratulations to the finalist and thank you to everyone who nominated.

Menstrual Health Innovation Shortlist

Founded by healthcare designer Kateřina Rydlová, who wanted to manage her own period pain without relying on medication, Body Moody has developed a discreet, wearable heated bodysuit that delivers targeted warmth to the abdomen and back – quietly, under everyday clothing.

Made from soft viscose, controlled via a companion app, and built for 200+ washes and over five years of use, the bodysuit is as practical as it is pioneering.

Their borrow-then-buy model lowers the barrier to entry and early customer feedback speaks for itself, with users reporting that they have gone from averaging multiple painkillers per cycle to needing none at all.

Eshe is a women’s health ecosystem built for a part of the world that femtech has long overlooked.

Rooted in Sub-Saharan Africa, where 69 per cent of global maternal deaths occur, 65 per cent of women and girls in Kenya cannot afford sanitary pads, and over 60 per cent of women lack access to preventive healthcare, Eshe was created to meet women where they are.

The Eshe app offers daily menstrual cycle and fertility tracking, pregnancy monitoring, mental wellbeing check-ins, in-app consultations with qualified doctors, and health education content, all in one place.

By identifying irregular cycles, missed periods and mental health changes, the platform nudges users toward timely action rather than emergency intervention.

Polycystic ovary syndrome (PCOS) affects almost one in five women, making it the leading cause of infertility and a significant risk factor for conditions spanning obesity, cardiovascular disease, cancer, and cognitive decline.

Despite this staggering burden, there has not been a new treatment option in seven decades – until now.

LoOoP is a bioelectronic device paired with the MyLoOoP companion app, designed to address both the metabolic and menstrual symptoms of PCOS with the ultimate ambition of avoiding, delaying, or reducing its long-term complications.

The MyLoOoP digital platform goes further still, combining evidence-backed content, clinically validated journaling tools, a validated phenotyping algorithm, and an inclusive community – closing the persistent gaps in PCOS diagnosis, information and care.

What happens next

The shortlist will be judge by a Premom representative who will announce the winner at a virtual event on June 19.

The winner will receive a trophy and be interviewed by a Femtech World journalist.

Continue Reading

Mental health

Dr-Julian helps deliver breakthrough mental health support for Black and ethnically minoritised mothers

Published

on

A groundbreaking digital perinatal mental health pilot for Black and ethnically minoritised women has helped women access support faster, complete therapy at higher rates, and recover more successfully than national averages.

The partnership between digital tech company Dr-Julian and The Essential Baby Company Ltd within a new model of mental health care named haPPIE SHE Cares  – who offer personalised support for women sharing their healthcare experiences, showed results well above NHS benchmarks for Black and ethnically minoritised women.

The pilot was created to help women who are less likely to use traditional mental health services during pregnancy and in the first year after giving birth.

By combining trusted community referrals, culturally aware support, and fast access to therapy through Dr-Julian’s online and virtual care platform, the programme delivered standout results.

Every woman who joined the pilot started therapy, 90 per cent completed treatment, and 74 per cent recovered; well above the NHS benchmark of around 52 per cent.

Women referred through community organisations accessed support in just one day on average, compared with around 21 days through many standard services.

Even the programme’s regular referral route reduced waits to 13 days.

The findings come as NHS leaders continue to focus on maternity inequalities and unequal access to mental health care.

Black and ethnically minoritised women can face barriers including stigma, language needs, lack of trust in services, childcare pressures, and difficulty navigating complex systems.

The haPPIE SHE Cares model was designed to break down those barriers by working with trusted community groups, offering culturally informed support, and where possible matching women with therapists who understood their background or language.

Gemma Poole for The Essential Baby Company said: “Too many women who need help feel unseen, unheard or unable to get support when they need it most.

“This project shows that when services are built around trust, culture and community, women engage, recover and thrive.

“This early success could provide a blueprint for reducing inequalities in maternal mental health care across the UK. Behind every statistic is a mother who felt supported, a family that benefited and a woman who found her voice.

“Mental healthcare must work for every community. This partnership shows that when high-quality therapy is combined with culturally responsive support, outcomes improve and women get help faster.

We are proud to have provided the therapists, virtual care systems and digital pathways behind this programme. We believe this model could help NHS organisations nationwide cut waiting times and improve recovery rates.”

Women who took part described the programme as life-changing, saying it reduced isolation, gave them confidence speaking with healthcare professionals, and made them more willing to seek help.

With growing pressure on maternity and mental health services, leaders behind the project say the pilot offers a practical solution that improves care while helping cut long waiting lists.

Plans are now being explored to expand the model through training, regional partnerships, and future funding.

Continue Reading

Diagnosis

Women unaware of gynaecological cancers

Published

on

Only one per cent of women can name all five gynaecological cancers, new research suggests, as 21 women in the UK die every day of the diseases.

The report also found that 31 per cent of women have put off or avoided seeking medical advice for gynaecological symptoms.

It also found that 43 per cent of women invited for cervical screening said barriers had put them off attending, while 18 per cent of respondents aged 25 to 34 who had been invited had never attended.

The five main gynaecological cancers are womb, also called uterine, ovarian, cervical, vulval and vaginal cancer.

The Lady Garden Foundation said that, while progress has been made since the UK government’s 2022 Women’s Health Strategy aimed to improve gynaecological cancer care, significant challenges remain.

John Butler, medical director and trustee at the Lady Garden Foundation, said: “The fact that only one per cent of the population can name the diseases that directly affect half of us underscores a significant awareness gap, impacting individuals’ ability to recognise vital signs and symptoms or seek timely medical help.

“Addressing this isn’t just about awareness; it’s a critical public health priority. Our collective efforts are essential to ensure the latest commitments announced by this government translate into tangible change that saves lives.”

The report said key reasons for delaying medical advice included difficulty making appointments, embarrassment and, for cervical screening, fear of pain or previous bad experiences.

Women also reported challenges within healthcare interactions, including feeling “not taken seriously”, “dismissed” or “not believed” when seeking gynaecological advice.

Jenny Halpern Prince, chief executive and charity co-founder, said: “We frequently hear reports of women feeling ‘not taken seriously,’ ‘dismissed,’ or ‘not believed’ when seeking gynaecological advice.

“These experiences highlight crucial areas where we can improve patient support and trust within our healthcare system, ensuring women receive the empathetic and effective care they need.”

The Lady Garden Foundation said it aims to increase awareness of both the charity and the five gynaecological cancers.

It also aims to serve as a primary entry point for reliable, stigma-free information, helping people understand their bodies, recognise symptoms and overcome barriers to accessing care.

Its Silent No More Garden was unveiled at the RHS Chelsea Flower Show 2026. Designed by Darren Hawkes, the garden serves as a national call to action, using five sculptures to spark conversations, break long-standing taboos and encourage open dialogue about symptoms and preventative care.

Butler said: “Continued focus and collaborative action are essential to progress.

“The ongoing commitment from the government, alongside societal efforts to break down taboos surrounding gynaecological health, are crucial.

“The Lady Garden Foundation is dedicated to being a beacon of information and support, empowering women with the knowledge they need. We urge everyone to learn the signs, speak up, and help us save lives.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.